Macular Degeneration: Clinical Trials

1,701 trials for Macular Degeneration, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

987 completed, 214 unknown, 166 terminated, 155 recruiting. 413 Phase 2, 313 Not applicable, 257 Phase 3, 251 Phase 1, 150 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 2413Completed 228, Terminated 66, Unknown 41, Recruiting 37, Active not recruiting 17, Withdrawn 16, Not yet recruiting 6, Enrolling by invitation 2
Not applicable313Completed 160, Unknown 55, Recruiting 36, Terminated 23, Not yet recruiting 18, Withdrawn 12, Active not recruiting 6, Enrolling by invitation 3
Phase 3257Completed 160, Unknown 30, Terminated 29, Recruiting 12, Active not recruiting 9, Withdrawn 9, Not yet recruiting 6, Enrolling by invitation 1, Suspended 1
Phase 1251Completed 145, Recruiting 34, Unknown 26, Terminated 23, Active not recruiting 12, Withdrawn 6, Not yet recruiting 4, Suspended 1
Phase 4150Completed 100, Unknown 23, Terminated 14, Withdrawn 5, Recruiting 4, Not yet recruiting 2, Active not recruiting 1, Enrolling by invitation 1
Early Phase 114Completed 4, Recruiting 4, Unknown 3, Not yet recruiting 2, Withdrawn 1

Follow Macular Degeneration: new trials by email Literature Review of Macular Degeneration trials Research Report on Macular Degeneration

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Remapping Text in Sentence and Word Tasks to Aid Reading With Central Vision Loss
Personalised Remapping Training, RSVP personalized remappi, Reading text in the wild with remapping - Macular Degeneration, Central Visual Impairment
Not applicableNot yet recruitingUniversity of Minnesota2162027-06-012026-10-29
Safety and Clinical Performance of the LENTISĀ® MAX LS-313 MF80 Compared With the Monofocal L-313 in Cataract Patients With Late Age-Related Macular Degeneration: A Multicenter Comparative Clinical Investigation.
Intraocular Lens - Cataract, AMD - Age-Related Macular Degeneration
Not applicableNot yet recruitingTeleon Surgical B.V.352027-02-012026-11-04
Non-invasive Ultrasound Retinal Stimulation for Vision Restoration
Non-invasive ultrasound retinal stimulation Device - Age-Related Macular Degeneration, Retinitis Pigmentosa
Not applicableNot yet recruitingUniversity of Southern California52027-01-102026-01-08
MIND-AMD Study: a Multidisciplinary Investigation of Neuroretinal Damage in Age-related Macular Degeneration.
Age-Related (Dry) Macular Degeneration, Age-Related Macular Degeneration (AMD)
Not yet recruitingIRCCS San Raffaele1602027-01-022026-09-29
Prevalence of Age-Related Macular Degeneration in Assiut University Hospitals
OCT - clear - Age-Related Macular Degeneration (AMD)
Not yet recruitingAssiut University902027-01-012026-10-21
Adaptive Optics Scanning Light Ophthalmoscopy (AOSLO) and Microperimetry (MP) Sub-study
Adaptive Optics Scanning Light Ophthalmoscopy, Microperimetry, Optical Coherence Tomography - Geographic Atrophy
Not applicableEnrolling by invitationUniversity of Wisconsin, Madison102026-11-052026-10-26
MacuMira Microcurrent Stimulation for Dark Adaptation in Dry Age-Related Macular Degeneration
Transpalpebral microcurrent electrical stimulation - Age-Related Macular Degeneration (AMD)
Not applicableNot yet recruitingClarity Eye Institute502026-11-042026-11-04
A Phase 1, First-in-Human Study of CITY-RBP4 in Healthy Volunteers and STGD1 Participants
CITY-RBP4, Placebo - Stargardt Disease 1, STGD1
Phase 1RecruitingCity Therapeutics482026-11-042026-11-12
OCT Macula Biomarkers Before Silicone Oil Removal and Visual Outcome After Silicone Oil Removal
Retinal Detachment, Macular Edema
Not yet recruitingAssiut University302026-11-012026-10-08
Phase 2a Study to Evaluate the Efficacy and Safety of SCAI-005 Ophthalmic Solution in Subjects With Neovascular Age-related Macular Degeneration
SCAI-005 0.04% 2drops TID, SCAI-005 0.08% 2drops TID, Placebo 2drops TID - wetAMD, Age Related Macular Degeneration
Phase 2Not yet recruitingSCAI Therapeutics502026-11-012026-05-26
A Study to Evaluate the Efficacy and Safety of VIS-101 in Participants With Neovascular Age-Related Macular Degeneration
VIS-101 6.0mg Low concentration, VIS-101 6.0mg High concentration, VIS-101 9.0mg High concentration - Neovascular Age Related Macular Degeneration(nAMD)
Phase 2Not yet recruitingEverest Medicines (China) Co.,Ltd.2442026-11-012026-11-05
A Clinical Trial to Evaluate the Efficacy and Safety of Bevemipretide Ophthalmic Topical Solution in Subjects Who Have Dry Age-Related Macular Degeneration (Dry AMD)
1 % Bevemipretide, 2% Bevemipretide, Vehicle - Dry AMD, Age-Related Macular Degeneration (AMD)
Phase 2 / Phase 3Not yet recruitingMighty Therapeutics, Inc.3002026-11-012026-11-09
Phase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-05)
OLN324, Ranibizumab - Wet Age-related Macular Degeneration
Phase 3Not yet recruitingOllin Biosciences, Inc.4002026-10-152026-09-11
Phase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-04)
OLN324, Aflibercept - Wet Age Related Macular Degeneration
Phase 3Not yet recruitingOllin Biosciences, Inc.5002026-10-152026-09-11
Iopidine to Decrease Intraocular Pressure Rise After Injections
Apraclonidine 1.0% ophthalmic solution - Macular Degeneration, Diabetic Retinopathy
Phase 4Not yet recruitingRetina Consultants of Delmarva1202026-10-012026-10-23
Photobiomodulation Laser for Reticular Pseudodrusen in Age-Related Macular Degeneration
Photobiomodulation Therapy, Sham Photobiomodulation - AMD - Age-Related Macular Degeneration
Not applicableNot yet recruitingFondazione G.B. Bietti, IRCCS672026-10-012026-09-04
A Case-Control Study Revealing Intraocular Microenvironment Characteristics in Patients With Ocular Diseases Based on Multi-Omics Analysis
Not applicable- observational study - Age- Related Macular Degeneration, Diabetic Retinopathy
Not yet recruitingFirst Affiliated Hospital of Zhejiang University1502026-10-012026-10-27
An Open-label Extension Study of the Long-Term Safety of Vonaprument (ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)
Vonaprument - Geographic Atrophy
Phase 3Not yet recruitingAnnexon, Inc.6052026-09-302026-09-08
Evaluation of PAN-90806 Eye Drops in Healthy Subjects
PAN-90806 Ophthalmic Solution, Vehicle Ophthalmic Solution - Wet Age Related Macular Degeneration, Neovascular (Wet) Age-Related Macular Degeneration
Phase 1Not yet recruitingZhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.202026-09-302026-08-14
A Phase 1/2 Study of the Safety and Efficacy of BRX011 Oral Administration Once Daily in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration
BRX011, Placebo - Geographic Atrophy
Phase 1 / Phase 2RecruitingBiojiva LLC1522026-09-292026-09-23

Showing 20 of 1701. Sign in to see all of them.

Narrower conditions

Macular Edema (418)  ·  Geographic Atrophy (179)  ·  Diabetic Retinopathy (153)  ·  Retinal Vein Occlusion (153)  ·  Choroidal Neovascularization (138)  ·  Retinal Diseases (99)  ·  Wet Macular Degeneration (93)  ·  Vision Disorders (69)  ·  Eye Diseases (68)  ·  Retinal Degeneration (67)  ·  Stargardt Disease (66)  ·  Diabetes Mellitus (64)  ·  Glaucoma (47)  ·  Cataract (46)

Broader conditions

Retinal Degeneration (1634)  ·  Eye Diseases (1633)  ·  Retinal Diseases (1602)  ·  Pathological Conditions, Signs and Symptoms (300)  ·  Cardiovascular Diseases (292)  ·  Vascular Diseases (292)  ·  Uveal Diseases (204)  ·  Endocrine System Diseases (198)  ·  Pathologic Processes (189)  ·  Metaplasia (163)  ·  Choroid Diseases (157)  ·  Diabetes Complications (154)  ·  Embolism and Thrombosis (153)  ·  Thrombosis (153)

Interventions

Ranibizumab (263)  ·  aflibercept (151)  ·  Bevacizumab (81)  ·  salicylhydroxamic acid (55)  ·  Dexamethasone (51)  ·  Calcium Dobesilate (40)  ·  Triamcinolone Acetonide (33)  ·  Verteporfin (32)  ·  pegaptanib (26)  ·  brolucizumab (22)  ·  Triamcinolone (20)  ·  Tomography, Optical Coherence (16)  ·  Photochemotherapy (14)  ·  Lutein (13)  ·  faricimab (13)

Sponsors

National Eye Institute (NEI) (78)  ·  Novartis Pharmaceuticals (66)  ·  Bayer (38)  ·  Allergan (37)  ·  Medical University of Vienna (27)  ·  Genentech, Inc. (25)  ·  Notal Vision Ltd. (21)  ·  Alcon Research (20)  ·  Hoffmann-La Roche (16)  ·  Johns Hopkins University (16)  ·  Pfizer (16)  ·  Duke University (13)  ·  GlaxoSmithKline (12)  ·  The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery (12)  ·  Regeneron Pharmaceuticals (11)

Countries

United States (770)  ·  Germany (154)  ·  France (152)  ·  United Kingdom (144)  ·  Italy (118)  ·  Canada (112)  ·  Australia (102)  ·  Spain (100)  ·  Austria (98)  ·  China (89)  ·  Israel (77)  ·  Hungary (69)  ·  Switzerland (64)  ·  Poland (63)  ·  South Korea (63)

Top investigators

Emily Y Chew, M.D. (9)  ·  Pablo Velazquez-Martin, MD (6)  ·  Peter A Campochiaro, MD (5)  ·  Thomas Ciulla, MD (5)  ·  Joel Naor, MD (4)

Results publications

PMID 37314061, PMID 37702300, PMID 32374423, PMID 22281388, PMID 25458728, PMID 30957581, PMID 32844399, PMID 34934034, PMID 39758130, PMID 23084240, PMID 23706949, PMID 25677668, PMID 33206392, PMID 33331670, PMID 35085502, PMID 36246941, PMID 36912792, PMID 39102242, PMID 39207600, PMID 11297486, PMID 15808240, PMID 17021318, PMID 17021319, PMID 19255158, PMID 19365036, PMID 19506188, PMID 20189654, PMID 20378094, PMID 20683380, PMID 20688734, PMID 20920825, PMID 21296824, PMID 21320967, PMID 21546089, PMID 21794843, PMID 22234714, PMID 22559899, PMID 22965590, PMID 23009891, PMID 23361508, PMID 23415775, PMID 23453513, PMID 23699977, PMID 23745581, PMID 24113783, PMID 24310343, PMID 24385141, PMID 24768239, PMID 24896137, PMID 25104651

NIH funding

2014 (12), 2019 (11), 2018 (6), 2009 (4), 2015 (4), 2017 (4), 2025 (4), 2005 (2), 2016 (2), U10EY014231 (2), U10EY018817 (2), U10EY024527 (2), 2023 (1), I01RX004563 (1), I21RX004099 (1)